Acquired long QT interval in athletes
https://doi.org/10.47529/2223-2524.2021.4.3
Abstract
Long QT syndrome (LQTS) is a common disorder that leads to dramatic patient outcomes, chief among which is sudden cardiac death. This review provides detailed data on the diagnosis, prevalence, classification, etiology. The variety of causes leading to LQTS creates difficulties in the differential diagnosis of this condition and, as a result, LQTS often remains outside the attention of physicians who monitor the health of athletes. Particular attention is paid to the acquired forms of LQTS, particularly, the drug-induced form. The results of studies aimed at studying the prevalence of LQTS and the effect of drugs on the QT interval are presented. The influence of non-steroidal anti-inflammatory drugs on the QT interval is discussed in detail because they are often used by athletes. The purpose of this review is to expand understanding of the etiology of LQTS and justify the need for careful ECG screening and pharmacological monitoring in athletes.
About the Authors
A. S. Yunisova
Russian State University of Physical Culture, Sports, Youth and Tourism
Russian Federation
Russian Federation
Alina S. Yunisova — M.D., Graduate student of the Department of Sports Medicine
4, Sirenevyi blvd., Moscow, 105122, Russia
A. V. Smolensky
Russian State University of Physical Culture, Sports, Youth and Tourism
Russian Federation
Russian Federation
Andrey V. Smolensky — M.D., D.Sc. (Medicine), Head of the Department of Sports Medicine
4, Sirenevyi blvd., Moscow, 105122 Russia
References
1. Ackerman M.J., Priori S.G., Willems S., Berul C., Brugada R., Calkins H., et al. HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13(8):1077–1109. https://doi.org/10.1093/ europace/eur245
2. Ackerman M.J. Long QT syndrome and sports participation: oil and water or an acceptable and manageable combination? JACC Clin. Electrophysiol. 2015;1(1–2):71–73. https://doi.org/10.1016/j.jacep.2015.03.009
3. Adler A., vander Werf C., Postema P.G., Rosso R., Bhuiyan Z.A., Kalman J.M., et al. Thephenomenon of ‘QT stunning’: The abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm. 2012;9(6):901–908. https://doi.org/10.1016/j.hrthm.2012.01.026
4. Bazett H.C. An analysis of time-relations of electrocardiograms. Heart. 1920;7:353–370.
5. Border W.L., Benson D.W. Sudden infant death syndrome and long QT syndrome: the zealots versus the naysayers. Heart Rhythm. 2007;4(2):167–169. https://doi.org/10.1016/j.hrthm.2006.12.019
6. Klivinyi C., Bornemann-Cimenti H. Pain medication and long QT syndrome. Korean J. Pain. 2018;31(1):3–9. https://doi.org/10.3344/kjp.2018.31.1.3
7. Corrado D., Basso C., Pavei A., Michieli P., Schiavon M., Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA. 2006; 296(13):1593–1601. https://doi.org/10.1001/jama.296.13.1593
8. Corrado D., Pelliccia A., Bjornstad H.H., Vanhees L., Biffi A., Borjesson M., et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Eur. Heart J. 2005;26(5): 516–524. https://doi.org/10.1093/eurheartj/ehi108
9. Corrado D., Basso C., Schiavon M., Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N. Eng. J. Med. 1998;339(6):364–369. https://doi.org/10.1056/NEJM199808063390602
10. Pelliccia A., Sharma S., Gati S., Bäck M., Börjesson M., Caselli S., et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur. Heart J. 2021;42(1):17–96. https://doi.org/10.1093/eurheartj/ehaa605
11. Digby G.C., Perez Riera A.R., Barbosa Barros R., Simpson C.S., Redfearn D.P., Methot M., et al. Acquired Long QT Interval: A Case Series of Multifactorial QT Prolongation. Clin. Cardiol. 2011;34(9):577–582. https://doi.org/10.1002/clc.20945
12. Mantovani G. Pseudohypoparathyroidism: Diagnosis and Treatment. J. Clin. Endocrinol. Metab. 2011;96(10):3020–3030. https://doi.org/10.1210/jc.2011-1048
13. Meyer T., Ruppert V., Karatolios K., Maisch B. Hereditary long QT syndrome due to autoimmune hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. J. Electrocardiol. 2007;40(6):504–509. https://doi.org/10.1016/j.jelectrocard.2006.12.013
14. Michels G., Kochanek M., Pfister R. Life-threatening cardiac arrhythmias due to drug-induced QT prolongation. Med. Klin. Intensivmed. Notfmed. 2016;111(4):302–309. https://doi.org/10.1007/s00063-015-0071-6
15. Mitchell J.H., Haskell W.L., Raven P.B. Classification of sports. J. Am. Coll Cardiol. 1994;24(4):864–866. https://doi.org/10.1016/0735-1097(94)90841-9
16. Molokhia M., Pathak A., Lapeyre-Mestre M., Caturla L., Montastruc J. L. L’Association Française des Centres Régionaux de Pharmacovigilance (CRPV), McKeigue P. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: Study in Southwest France. Br. J. Clin Pharmacol. 2008;66(3):386–395. https://doi.org/10.1111/j.1365-2125.2008.03229.x
17. Moss A.J. Long QT syndrome. JAMA. 2003;289(16):2041–2044. https://doi.org/10.1001/jama.289.16.2041
18. Moss A.J., Schwartz P.J., Crampton R.S., Tzivoni D., Locati E.H., MacCluer J., et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991;84(3):1136–1144. https://doi.org/10.1161/01.cir.84.3.1136
19. Napolitano C., Priori S.G., Schwartz P.J., Bloise R., Ronchetti E., Nastoli J., et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005;294(23):2975–2980. https://doi.org/10.1001/jama.294.23.2975
20. Newman D.B., Fidahussein S.S., Kashiwagi D.T., Kennel K.A., Kashani K.B., Zhen Wang, et al. Reversible cardiac dysfunction asso-ciated with hypocalcemia: a systematic review and meta-analysis of individual patient data. Heart Fail. Rev. 2014;19(2):199–205. https://doi.org/10.1007/s10741-013-9371-1
21. Pathak A., Boveda S., Defaye P., Mansourati J., Mallaret M., Thebault L., et al. Celecoxib-associated torsade de pointes. Ann Pharmacother. 2002;36(7–8):1290–1291. https://doi.org/10.1345/aph.1A429
22. Pelliccia A., Fagard R., Bjørnstad H.H., Anastassakis A., Arbustini E., Assanelli D., et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur. Heart J. 2005;26(14):1422–1445. https://doi.org/10.1093/eurheartj/ehi325
23. Priori S.G., Blomström-Lundqvist C., Mazzanti A., Blom N., Borggrefe M., Camm J., et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2015;36(41):2793–2867. https://doi.org/10.1093/eurheartj/ehv316
24. Priori S.G., Schwartz P.J., Napolitano C., Bloise R., Ronchetti E., Grillo M., et al. Risk Stratification in the Long-QT Syndrome. N. Engl. J. Med. 2003;348(19):1866–1874. https://doi.org/10.1056/nejmoa022147
25. Priori S.G., Wilde A.A., Horie M., Cho Y., Behr E.R., Berul C., et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10(12):e85–e108. https://doi.org/10.1016/j.hrthm.2013.07.021
26. Kim J.A., Chelu M.G. Inherited Arrhythmia Syndromes. Tex Heart Inst J. 2021 Sep 1;48(4):e207482. https://doi.org/10.14503/THIJ-20-7482.
27. Nakano Y., Shimizu W. Genetics of long-QT syndrome. J. Hum. Genet. 2016;61(1):51–55. https://doi.org/10.1038/jhg.2015.74
28. Rajab A., Straub V., McCann L.J., Seelow D., Varon R., Barresi R., et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 2010;6(3):e1000874. https://doi.org/10.1371/journal.pgen.1000874
29. Roden D.M. Predicting drug-induced QT prolongation and torsades de pointes. J. Physiol. 2016;594(9):2459–68. https://doi.org/10.1113/JP270526
30. Basavarajaiah S., Wilson M., Whyte G., Shah A., Behr E., Sharma S. Prevalence and significance of an isolated long QT interval in elite athletes. Eur. Heart J. 2007;28(23):2944–2949. https://doi.org/10.1093/eurheartj/ehm404
31. Schwartz P.J., Woosley R.L. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. J. Am. Coll. Cardiol. 2016;67(13):1639–1650. https://doi.org/10.1016/j.jacc.2015.12.063
32. Schwartz P.J., Moss A.J., Vincent G.M., Crampton R.S. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993;88(2):782–784. https://doi.org/10.1161/01.cir.88.2.782
33. Schwartz P.J., Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation. 2011;124(20):2181–2184. https://doi.org/10.1161/CIRCULATIONAHA.111.062182
34. Sharma S., Whyte G., Elliott P., Padula M., Kaushal R., Mahon N., McKenna W.J. Electrocardiographic changes in 1000 highly trained junior elite athletes. Br. J. Sports Med. 1999;33(5):319–324. https://doi.org/10.1136/bjsm.33.5.319
35. Straus M., Sturkenboom M.C., Bleumink G.S., Dieleman J.P., van der Lei J., de Graeff P.A., et al. Non-cardiac QTcprolonging drugs and the risk of sudden cardiac death. Eur. Heart J. 2005;26(19):2007–2012. https://doi.org/10.1093/eurheartj/ehi312
36. Maury P., Delasnerie H., Beneyto M., Rollin A. Autonomic cardiac innervation: impact on the evolution of arrhythmias in inherited cardiac arrhythmia syndromes. Herzschrittmacherther Elektrophysiol. 2021 Sep;32(3):308–314. English. https://doi.org/10.1007/s00399-021-00774-3 Epub 2021 Jun 29.
37. Turan S. Current nomenclature of pseudohypoparathyroidism: inactivating parathyroid hormone / parathyroid hormonerelated protein signaling disorder. J. Clin. Res. Pediatr. Endocrinol. 2017;9(2):58–68. https://doi.org/10.4274/jcrpe.2017.s006
38. Underbjerg L., Sikjaer T., Mosekilde L., Rejnmark L. Pseudohypoparathyroidism — epidemiology, mortality and risk of complications. Clin. Endocrinol (Oxf.). 2016;84(6):904–911. https://doi.org/10.1111/cen.12948
39. Vatta M., Ackerman M.J., Ye B., Makielski J.C., Ughanze E.E., Taylor E.W., et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation. 2006;114(20):2104–2112. https://doi.org/10.1161/CIRCULATIONAHA.106.635268
40. Viskin S., Postema P.G., Bhuiyan Z.A., Rosso R., Kalman J.M., Vohra J.K., et al. The response of the QT interval to the brief tachycardia provoked by standing: A bedside test for diagnosing long QT syndrome. J. Am. Coll. Cardiol. 2010;55(18):1955–1961. https://doi.org/10.1016/j.jacc.2009.12.015
41. World Anti-Doping Agency. Prohibited List, Yanuary 2016 [Internet]. Available at: https://www.fia.com/sites/default/files/wada-2016-prohibited-list-en_0.pdf (accessed April 24, 2016).
42. Wedekind H., Burde D., Zumhagen S., Debus V., Burkhardtsmaier G., Mönnig G., Breithardt G, Schulze-Bahr E. QT interval prolongation and risk for cardiac events in genotyped LQTS-index children. Eur. J. Pediatr. 2009;168(9):1107–1115. https://doi.org/10.1007/s00431-008-0896-6
43. Zipes D.P., Ackerman M.J., Estes N.A. 3rd, Grant A.O., Myerburg R.J., Van Hare G. Task Force 7: arrhythmias. J. Am. Coll. Cardiol. 2005;45(8):1354–1363. https://doi.org/10.1016/j.jacc.2005.02.014
Review
For citations:
Yunisova A.S., Smolensky A.V. Acquired long QT interval in athletes. Sports medicine: research and practice. 2021;11(4):17-25. (In Russ.) https://doi.org/10.47529/2223-2524.2021.4.3
Views:
1075
Email this article 